American Journal of Kidney Diseases
Volume 53, Issue 4, Supplement 4 , Pages S3-S10 , April 2009

Plasma Parathyroid Hormone Level and Prevalent Cardiovascular Disease in CKD Stages 3 and 4: An Analysis From the Kidney Early Evaluation Program (KEEP)

  • Rohit Bhuriya, MD

      Affiliations

    • Department of Medicine, Chicago Medical School, North Chicago, IL
    • ,
  • Suying Li, PhD

      Affiliations

    • Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN
    • ,
  • Shu-Cheng Chen, MS

      Affiliations

    • Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN
    • ,
  • Peter A. McCullough, MD, MPH

      Affiliations

    • Division of Cardiology, William Beaumont Hospital, Royal Oak, MI
    • Division of Nutrition, William Beaumont Hospital, Royal Oak, MI
    • Preventive Medicine, Department of Medicine, William Beaumont Hospital, Royal Oak, MI
    • ,
  • George L. Bakris, MD

      Affiliations

    • Hypertensive Diseases Unit, Department of Medicine, University of Chicago, Pritzker School of Medicine, Chicago, IL
    • Corresponding Author InformationAddress correspondence to George L. Bakris, MD, University of Chicago School of Medicine, 5841 S Maryland Ave, MC 1027, Chicago, IL 60637

Received 16 October 2008 ,Accepted 19 November 2008.

References 

  1. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–663
  2. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–482
  3. Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005;20:1048–1056
  4. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  5. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31:607–617
  6. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol. 2005;16:1115–1125
  7. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–1953
  8. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: The Tromso Study. Eur J Cardiovasc Prev Rehabil. 2004;11:69–74
  9. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 1999;56:383–392
  10. Usdin TB, Bonner TI, Harta G, et al. Distribution of parathyroid hormone-2 receptor messenger ribonucleic acid in rat. Endocrinology. 1996;137:4285–4297
  11. Smogorzewski M. PTH, chronic renal failure and myocardium. Miner Electrolyte Metab. 1995;21:55–62
  12. Ogino K, Burkhoff D, Bilezikian JP. The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein. Endocrinology. 1995;136:3024–3030
  13. Schluter KD, Piper HM. Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. Am J Physiol. 1992;263:H1739–H1746
  14. Amann K, Ritz E, Wiest G, et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol. 1994;4:1814–1819
  15. Saleh FN, Schirmer H, Sundsfjord J, et al. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J. 2003;24:2054–2060
  16. Akmal M, Kasim SE, Soliman AR, et al. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int. 1990;37:854–858
  17. Liang K, Oveisi F, Vaziri ND. Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int. 1998;53:626–630
  18. Akmal M, Massry SG, Goldstein DA, et al. Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest. 1985;75:1037–1044
  19. Fadda GZ, Hajjar SM, Perna AF, et al. On the mechanism of impaired insulin secretion in chronic renal failure. J Clin Invest. 1991;87:255–261
  20. Schleiffer R, Pernot F, Jones R. Endothelium is a target organ of parathyroid secretions in genetic hypertensive rats. Horm Metab Res. 1995;27:16–18
  21. Noda M, Katoh T, Kurokawa K, et al. Increased expression of parathyroid hormone-related peptide gene in blood vessels of spontaneously hypertensive rats. Hypertension. 1997;30:1284–1288
  22. Barenbrock M, Spieker C, Laske V, et al. Studies of the vessel wall properties in hemodialysis patients. Kidney Int. 1994;45:1397–1400
  23. Rostand SG, Sanders C, Kirk KA, et al. Myocardial calcification and cardiac dysfunction in chronic renal failure. Am J Med. 1988;85:651–657
  24. Ejerblad S, Eriksson I, Johansson H. Uraemic arterial disease (An experimental study with special reference to the effect of parathyroidectomy). Scand J Urol Nephrol. 2008;13:161–169
  25. Jurkovitz CT, Qiu Y, Wang C, et al. The Kidney Early Evaluation Program (KEEP): Program design and demographic characteristics of the population. Am J Kidney Dis. 2008;51(suppl 2):S3–S12
  26. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254
  27. Stevens LA, Stoycheff N. Standardization of serum creatinine and estimated glomerular filtration rate in the National Kidney Foundation Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008;51(suppl 2):S77–S82
  28. McCullough PA, Jurkovitz CT, Pergola PE, et al. Independent components of chronic kidney disease as a cardiovascular risk state: Results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007;167:1122–1129
  29. Giovannucci E, Liu Y, Hollis BW, et al. 25-Hydroxyvitamin D and risk of myocardial infarction in men: A prospective study. Arch Intern Med. 2008;168:1174–1180
  30. Andress DL. Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation. Kidney Int. 2006;69:33–43
  31. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117:503–511
  32. Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: Data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167:1159–1165
  33. Joly D, Drueke TB, Alberti C, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: A cross-sectional study. Am J Kidney Dis. 2008;51:987–995
  34. Souberbielle JC, Boutten A, Carlier MC, et al. Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int. 2006;70:345–350

PII: S0272-6386(09)00025-0

doi: 10.1053/j.ajkd.2008.11.029

American Journal of Kidney Diseases
Volume 53, Issue 4, Supplement 4 , Pages S3-S10 , April 2009

Article Tools

* Image Usage & Resolution